Investorideas.com
Search  Follow Investorideas on Twitter  Investorideas is on Facebook  Investorideas is on Google Plus  Investorideas is on Youtube  Investorideas is on Pinterest  Investorideas is on tumblr  Investorideas is on LinkedIn  Investorideas RSS 


Investorideas podcasts on iTunes, Google Play Music and iHeart.com


Scythian Biosciences Corp. (TSXV: $SCYB.V) Announces Bart Oates, 5-time #NFL Pro Bowl player and a 3-time Super Bowl Champion Joins Professional Athlete Advisory Committee

Investorideas Featured Company: Scythian Biosciences Corp. (TSX.V: SCYB)

 

TORONTO - October 2, 2017 (Investorideas.com Newswire) Scythian Biosciences Corp. (the "Company") (TSXV: SCYB) announces the formation of its Professional Athlete Advisory Committee and the first appointment ,with Bart Oates, a 5-time NFL Pro Bowl player and a 3-time Super Bowl Champion joining the new Committee. The purpose of this committee is to bring together various, current, and former pro-athletes who have experienced or share concern for the pain and suffering associated with concussions that occur during sports competitions.

"The member's intimate knowledge and personal experience will lend Scythian and our research partners at the University of Miami great insight into the world of sports and the aftermath of head injuries. Bart Oates, who has been an Advisory Board member will head up this committee and lead in recruiting new inductees from Professional Football, Hockey, Basketball, Boxing, Soccer and more," commented Mr. Jonathan Gilbert, CEO of the Company.

About Mr. Oates

A former center for the New York Giants and San Francisco 49ers, Bart Oates is a 5-time NFL Pro Bowl player and a 3-time Super Bowl Champion. Once finished with football, Mr. Oates took law classes and then worked as an attorney, receiving his law degree from Seton Hall University. Mr. Oates maintains an active role in many services to the community, including serving as President of the NY/NJ Chapter of the NFL Alumni Association.

Stock Options

The Company has also issued 62,500 incentive stock options to an officer and advisors of the Company entitling the grantees to purchase up to 62,500 common shares of the Company at an exercise price of $8.00 per share for a period of five years. The options are subject to certain vesting provisions and are subject to regulatory approval.

About Scythian Biosciences Corp.

Scythian is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination.

Scythian's mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen. The University of Miami believes that Scythian's scientific approach shows significant promise and differs from previous approaches to treat this growing problem. The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian's clinical studies to be undertaken at their world-class facilities

Gillian A. Hotz, PhD, is leading Scythian's program at the University of Miami. Dr. Hotz is a nationally recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation. She has extensive experience in neurocognitive testing. Dr. Hotz has been the co-director of University of Miami Miller School of Medicine's Concussion Program since 1995.

Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This press release may contain certain forward-looking information and statements ("forward-looking information") within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, its securities, or financial or operating results (as applicable). Although the Company believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company's control, including the risk factors discussed in the Filing Statement and the registration statement which are incorporated herein by reference and are available through SEDAR at www.sedar.com and on the SEC EDGAR filing service at www.sec.gov. The forward-looking information contained in this press release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

For further information, please contact:

Scythian Biosciences Corp.
Jonathan Gilbert
CEO
Phone: (212) 729-9208
Email: info@scythianbio.com

Scythian Biosciences Corp. (TSX.V: SCYB)

is a Featured biotech and marijuana company on Investorideas.com

Visit Profile page: http://www.investorideas.com/CO/SCYB/

Get News Alerts on Scythian Biosciences Corp.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details - http://www.investorideas.com/About/News/Clientspecifics.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.



Questrade Democratic Pricing - 1 cent per share, $4.95 min / $9.95 max



Join Investor Ideas Members to access the Renewable Energy stocks directory, water stocks, biotech stocks, defense stocks directories and the Insiders Corner